.jpeg?#)
Novartis Q1 earnings: Company raises 2025 bar after beating sales expectations
Novartis is starting the year on a strong note as several of its core medicines beat Wall Street’s sales projections, prompting the drugmaker to shift its full-year guidance to a higher bar. In the first ...
Novartis is starting the year on a strong note as several of its core medicines beat Wall Street’s sales projections, prompting the drugmaker to shift its full-year guidance to a higher bar.
In the first ...
